[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654699":3},{"organization":4,"outcomesModule":7,"designInfo":51,"detailedDescription":54,"studyPopulation":55,"armGroups":56,"interventions":50,"overallOfficials":60,"centralContacts":65,"locations":74,"responsibleParty":166,"collaborators":168,"id":171,"slug":172,"hasResults":173,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":50,"eligibilityCriteria":177,"healthyVolunteers":173,"sex":178,"minAge":179,"maxAge":50,"enrollmentInfo":180,"targetDuration":183,"studyType":184,"phases":50,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":194,"whyStopped":50,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":204},{"fullName":5,"class":6},"NHS Greater Glasgow and Clyde","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":50},[9],{"measure":10,"description":11,"timeFrame":12},"Seattle Angina Questionnaire","The Seattle Angina Questionnaire a validated 19-item patient-reported survey used to measure coronary artery disease and angina treatment efficacy. Patients will complete on paper or electronically. The scores range from 0 to 100, with higher scores indicating less frequent angina, improved function, and better quality of life","Enrolment",[14,17,20,23,26,29,32,36,39,42,46],{"measure":15,"description":16,"timeFrame":12},"Brief Illness perception Questionnaire (Brief IPQ)","A nine-item scale designed to rapidly assess the cognitive and emotional representations of illness. It consists of 9 items: 8 are scored on a 0-10 scale, and item 9 is an open-ended question assessing perceived causes. The total score (0-80) is calculated by summing the first 8 items, with items 3, 4, and 7 reverse scored. Higher scores generally reflect a more threatening perception of the illness",{"measure":18,"description":19,"timeFrame":12},"Patient Health Questionnaire-4 of (PHQ4)","An ultra-brief screening tool used to assess core symptoms of anxiety and depression. Higher scores indicate greater feelings of anxiety and depression.",{"measure":21,"description":22,"timeFrame":12},"Duke Activity Status Index (DASI)","A 12-item, self-administered questionnaire used to estimate a patient's functional capacity and peak oxygen uptake. Scores range from 0 to 58.2, with higher scores indicating better physical fitness and lower risk",{"measure":24,"description":25,"timeFrame":12},"EQ-5D (EQ-5D-5L)","The EQ-5D evaluates health across 5 domains (mobility, self-care, usual activities, pain\u002Fdiscomfort, anxiety\u002Fdepression). It yields three metrics: a 5-digit health profile string, a weighted index value, and a 0-100 self-rated Visual Analogue Scale (VAS) score.\n\nFor the 5-digit health profile string higher individual numbers indicate worse health problems.\n\nFor the weighted index value a score of 1 indicates perfect health, while 0 represents death.\n\nFor the visual analogue score higher numbers here indicate better health",{"measure":27,"description":28,"timeFrame":12},"Treatment Satisfaction Questionnaire for Medication (TSQM)","Measures patient satisfaction with their prescription medications. It evaluates core aspects of a patient's treatment experience, including effectiveness, side effects, convenience, and overall satisfaction. Individual item scores within each domain are summed and transformed into a standardized scale from 0 to 100, where higher scores mean greater treatment satisfaction",{"measure":30,"description":31,"timeFrame":12},"The Montreal Cognitive Assessment (MoCA)","30-point medical screening test used by health professionals to detect early signs of mild cognitive impairment and dementia. It covers domains such as memory, visuospatial awareness, executive function, attention, language and orientation to place and time. Higher scores indicate better cognitive function with scores 30-26 indicating normal function, 25-18 indicating mild cognitive impairment and below 18 indicating potential thinking and memory problems.",{"measure":33,"description":34,"timeFrame":35},"Sex specific cardiovascular risk score - Heart age score","Heart age score can indicate chance of having a heart attack, stroke or developing heart disease. It uses height, weight, blood pressure, cholesterol levels and family history of disease to calculate a heart age. If the age of participant's heart is older than their actual age, they are at higher risk for developing a heart condition. The investigators want to understand if women have sex specific risks.","Across 25 years",{"measure":37,"description":38,"timeFrame":35},"Sex specific cardiovascular risk score - QRisk score","QRISK is a calculation to estimate participants' risk of developing cardiovascular disease over the next 10 years. It uses information such as age, sex, ethnic background, where participants live, smoking status, weight, existing medical conditions, family history and blood pressure to calculate a score. A score of less than 10% indicates low risk, 10-20% indicates moderate risk and 20% or higher indicates higher risk of developing heart disease over the next 10 years. The investigators want to understand if women have sex specific risks.",{"measure":40,"description":41,"timeFrame":35},"Sex specific cardiovascular risk score - EuroSCORE II","EuroSCORE II a risk assessment tool that estimates the percentage risk of dying during or shortly after major heart surgery. It uses patient related factors such as age, gender, presence of chronic kidney disease, diabetes and poor mobility. Cardiac related factors such as presence of recent heart attack, how well the heart pumps blood and pulmonary hypertension (high blood pressure in the arteries that carry blood from your heart to your lungs), and operation related factors such as how urgent the procedure is. The final score is expressed as a percentage representing the predicted probability of dying in hospital. Scores under 2% represent low predicted risk, Scores between 2% and 5% reflect a moderate risk level and scores of 6% or higher place a patient in a higher-risk category, where the complexity or underlying conditions significantly elevate risk. The investigators want to understand if women have sex specific risks.",{"measure":43,"description":44,"timeFrame":45},"Dementia risk score","We will use UK Biobank Dementia Risk Score (UKBDRS) to understand participant's risk of dementia. Items such as age, education, smoking history and medication use are considered to give a score. Higher scores describes a higher probability of dementia within the next 14 years but is not a clinical diagnosis.","Baseline",{"measure":47,"description":48,"timeFrame":49},"Episodes of care","We will record how often the participants see their medical providers and for which reason","Over 25 years",null,{"allocation":50,"interventionModel":50,"interventionModelDescription":50,"primaryPurpose":50,"observationalModel":52,"timePerspective":53,"maskingInfo":50},"COHORT","PROSPECTIVE","There is a paucity of evidence of long term outcomes of women with ANOCA or understanding of the potentially unique mechanisms which could drive ANOCA in women specifically.\n\nIn order to understand the impact of ANOCA, and related endotypes, on an individual's wellbeing and the related healthcare needs, follow-up for vital status, episodes of care (primary and secondary care) and medication use is vital.\n\nThe availability of electronic health records in the NHS is enabling for this purpose and without the need to contact patients. Accordingly, in ANOCA Diagnosis, women will be followed up without requiring further visits post enrolment.\n\nFurthermore, allowing endotyping of the ANOCA allows for targeted treatments. Women in this trial will be approached for participation in future research studies for potential new treatments for ANOCA.","The study population will include women of biological female sex with ANOCA and the participants should have a diagnosis of microvascular angina and\u002For vasospastic angina and an endotype defined by recent diagnostic tests within one year of enrolment.",[57],{"label":58,"type":50,"description":59,"interventionNames":50},"Cohort 1","Women with ANOCA",[61],{"name":62,"affiliation":63,"role":64},"Colin Berry, PhD","The University of Glasgow","PRINCIPAL_INVESTIGATOR",[66,71],{"name":67,"role":68,"phone":69,"phoneExt":50,"email":70},"Clare Dolan","CONTACT","0141 314 4328","clare.dolan3@nhs.scot",{"name":72,"role":68,"phone":69,"phoneExt":50,"email":73},"PMU Mail box","ggc.pmu.research@nhs.scot",[75,86,94,102,116,124,132,137,142,150,158],{"facility":76,"status":50,"city":77,"state":50,"zip":50,"country":78,"countryCode":79,"cosmosGeoPoint":80,"geoPoint":85,"contacts":50},"Essex cardiothoracic centre","Basildon","United Kingdom","UK",{"type":81,"coordinates":82},"Point",[83,84],0.45782,51.56844,{"lat":84,"lon":83},{"facility":87,"status":50,"city":88,"state":50,"zip":50,"country":78,"countryCode":79,"cosmosGeoPoint":89,"geoPoint":93,"contacts":50},"Royal United Hospital Bath","Bath",{"type":81,"coordinates":90},[91,92],-2.36172,51.3751,{"lat":92,"lon":91},{"facility":95,"status":50,"city":96,"state":50,"zip":50,"country":78,"countryCode":79,"cosmosGeoPoint":97,"geoPoint":101,"contacts":50},"Royal Papworth Hospital","Cambridge",{"type":81,"coordinates":98},[99,100],0.11667,52.2,{"lat":100,"lon":99},{"facility":103,"status":50,"city":104,"state":50,"zip":105,"country":78,"countryCode":79,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Queen Elizabeth University Hospital Clinical Research Facility,","Glasgow","G51 4TF",{"type":81,"coordinates":107},[108,109],-4.25763,55.86515,{"lat":109,"lon":108},[112],{"name":113,"role":68,"phone":114,"phoneExt":50,"email":115},"Colin Berry","0141 232 7600","Colin.Berry@glasgow.ac.uk",{"facility":117,"status":50,"city":118,"state":50,"zip":50,"country":78,"countryCode":79,"cosmosGeoPoint":119,"geoPoint":123,"contacts":50},"Leeds General Infirmary","Leeds",{"type":81,"coordinates":120},[121,122],-1.54785,53.79648,{"lat":122,"lon":121},{"facility":125,"status":50,"city":126,"state":50,"zip":50,"country":78,"countryCode":79,"cosmosGeoPoint":127,"geoPoint":131,"contacts":50},"Brompton Hospital","London",{"type":81,"coordinates":128},[129,130],-0.12574,51.50853,{"lat":130,"lon":129},{"facility":133,"status":50,"city":126,"state":50,"zip":50,"country":78,"countryCode":79,"cosmosGeoPoint":134,"geoPoint":136,"contacts":50},"Guys and St Thomas Hospital",{"type":81,"coordinates":135},[129,130],{"lat":130,"lon":129},{"facility":138,"status":50,"city":126,"state":50,"zip":50,"country":78,"countryCode":79,"cosmosGeoPoint":139,"geoPoint":141,"contacts":50},"Kings college london",{"type":81,"coordinates":140},[129,130],{"lat":130,"lon":129},{"facility":143,"status":50,"city":144,"state":50,"zip":50,"country":78,"countryCode":79,"cosmosGeoPoint":145,"geoPoint":149,"contacts":50},"Freeman Hospital","Newcastle upon Tyne",{"type":81,"coordinates":146},[147,148],-1.61396,54.97328,{"lat":148,"lon":147},{"facility":151,"status":50,"city":152,"state":50,"zip":50,"country":78,"countryCode":79,"cosmosGeoPoint":153,"geoPoint":157,"contacts":50},"Nottingham City Hospital","Nottingham",{"type":81,"coordinates":154},[155,156],-1.15047,52.9536,{"lat":156,"lon":155},{"facility":159,"status":50,"city":160,"state":50,"zip":50,"country":78,"countryCode":79,"cosmosGeoPoint":161,"geoPoint":165,"contacts":50},"Sunderland Royal Hospital","Sunderland",{"type":81,"coordinates":162},[163,164],-1.38222,54.90465,{"lat":164,"lon":163},{"type":167,"investigatorFullName":50,"investigatorTitle":50,"investigatorAffiliation":50,"oldNameTitle":50,"oldOrganization":50},"SPONSOR",[169],{"name":63,"class":170},"UNKNOWN","100654699","diagnosis-of-women-with-anoca-100654699",false,"NCT07802457","Diagnosis of Women With ANOCA","Diagnosis of Women With ANOCA: a Registry-based Cohort Study","Inclusion Criteria:\n\n* ANOCA endotype0\n* Myocardial perfusion reserve or coronary flow reserve recorded within one year\n* Seattle Angina Questionnaire frequency score \\\u003C100\n* Female sex\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Unable to provide informed consent\n* Unable to comply with the protocol","FEMALE","18 Years",{"count":181,"type":182},400,"ESTIMATED","25 Years","OBSERVATIONAL","Angina is a feeling of chest pain or discomfort which can happen if there is reduced blood flow to the heart. Patients can experience angina with no obstructive coronary arteries (ANOCA) which is a difficult condition to treat (ie relieve angina) since few randomised, controlled therapy trials have been undertaken for ANOCA.\n\nUntil now, angina has been mainly studied in men even though women are at least two-fold more likely than men to experience ANOCA.\n\nResearch studies involving people with ANOCA may have limitations in relation to retrospective collection of historical data or lack of prospectively collected contemporary data. These limitations are particularly relevant to women with ANOCA which is an area that has been historically under-recognised.\n\nPrior studies may have data gaps, such as for women's health. For these reasons, the Investigators propose a research registry for women with ANOCA which aims to plug these gaps. The Investigators aim to understand the biological mechanisms behind angina in women specifically.\n\nThis study will categorise ANOCA into different subtypes and offer women the opportunity to take part in research studies to treat ANOCA. The Investigators will also follow the women's health over time through remote data collection methods.",[187],"Angina With No Obstructive Coronary Artery Disease",[189,190,191,192,193],"Angina","Cardiovascular disease","Cohort study","Endotype","Women","NOT_YET_RECRUITING","2026-09-01",{"date":197,"type":198},"2026-09-03","ACTUAL",{"date":200,"type":182},"2026-11-27",{"date":202,"type":182},"2029-06-30",{"name":5,"class":6},11]